An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy

Hoffmann-La Roche57 enrolled

Overview

This prospective, multicenter observational study will evaluate the efficacy, safety, and tolerability of Tarceva (erlotinib) as second-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after pemetrexed-containing first-line chemotherapy. Eligible patients will be followed until withdrawal of consent, lost-to-follow-up, or study termination, whichever occurs first.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

ErlotinibDRUG

Erlotinib was supplied as tablets in the retail product Tarceva.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients ≥ 18 years of age. * Histologically or cytologically documented locally advanced or metastatic non-small cell lung cancer (inoperable Stage III or IV according to the 7th TNM Classification of Malignant Tumors). * Experiencing disease progression after pemetrexed-containing first-line chemotherapy regimen. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Initiated on second-line treatment with Tarceva at the most 4 weeks prior to study entry at baseline (date of signature of informed consent). Exclusion Criteria: * Prior chemotherapy/targeted therapy after disease progression after first-line treatment in the advanced non-small cell lung cancer (NSCLC) setting. * Contraindication for Tarceva according to the Summary of Product characteristics.

Locations (21)

Unnamed facility

Aalst, Belgium

Unnamed facility

Antwerp, Belgium

Unnamed facility

Boussu, Belgium

Unnamed facility

Brussels, Belgium

Unnamed facility

Charleroi, Belgium

Unnamed facility

Dendermonde, Belgium

Unnamed facility

Duffel, Belgium

Unnamed facility

Edegem, Belgium

Unnamed facility

Frameries, Belgium

Unnamed facility

Genk, Belgium

...and 11 more locations

Outcomes

Primary Outcomes

Progression-free Survival

Progression-free survival was defined as the time from the first dose of erlotinib to disease progression or death from any cause, whichever occurred earlier. Progressive disease was defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter of target lesions recorded since treatment started, or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame: Baseline to the end of the study (up to 2 years)

Secondary Outcomes

Best Overall Response

Reported are the percentage of participants with a best overall response of complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). The best overall response to treatment was determined by the Response Evaluation Criteria in Solid Tumors (RECIST). A CR was defined as the disappearance of all target lesions (TL) or the disappearance of all non-TLs. A PR was defined as at least a 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since treatment started for TLs and the persistence of 1 or more non-TL(s). PD was defined as at least a 20% increase in the SLD of TLs, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs.

Time frame: Baseline to the end of the study (up to 2 years)

Overall Survival

Overall survival was defined as the time from Baseline until death from any cause.

Time frame: Up to 2 years

Percentage of Participants Who Developed Rash

Time frame: Up to 2 years

Percentage of Participants Who Developed Diarrhea

Time frame: Up to 2 years